trending Market Intelligence /marketintelligence/en/news-insights/trending/b8j1uWOwARmhAlftZDHVUg2 content esgSubNav
In This List

Former Juniper exec joins 2X Oncology as CEO

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Former Juniper exec joins 2X Oncology as CEO

2X Oncology Inc. named George Elston as CEO and a board member.

Elston was previously CFO of Juniper Pharmaceuticals Inc.

2X Oncology is a clinical stage company developing targeted therapeutics that leverage proprietary drug response predictor companion diagnostic technology to address unmet needs in women's cancer.